Skip to product information

Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024

Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024

Regular price $40.00 USD
Regular price $40.00 USD Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024

Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024

Regular price $40.00
Regular price $40.00 Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    Meetings Events & Conference Coordinators 19th Annual New Orleans Summer Cancer Meeting 2024


    Annual New Orleans Summer Cancer Meeting 2024

    Include: 57 videos, size: 7.52 GB
    Target Audience: oncologists, hematologists, radiation oncologists, surgical oncologists
    Information:


    The 19th Annual New Orleans Summer Cancer Meeting (NOSCM) 2024 will take place from July 19-21, 2024, at The Roosevelt Hotel in New Orleans, Louisiana. This event will focus on improving cancer survival rates through prevention, early detection, targeted therapy, and comprehensive survivorship care. The program will cover a wide range of topics, including advancements in cancer genetics, neuro-oncology, gastrointestinal and genitourinary cancers, immunotherapy, and more.


    The 19th Annual New Orleans Summer Cancer Meeting (NOSCM) 2024 is designed for a diverse group of professionals involved in oncology. The target audience includes:
    • Oncologists
    • Hematologists
    • Radiation oncologists
    • Surgical oncologists
    • Medical oncologists
    • Oncology nurses
    • Pharmacists
    • Researchers
    • Other healthcare professionals involved in cancer care

    This meeting aims to provide the latest updates and advancements in cancer treatment, prevention, and survivorship care.

    Annual New Orleans Summer Cancer Meeting 2024

    Topics:
    • Acquired Inhibitors in Cancer- State-of-the Art Management.mp4
      Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship- An Integrative Approach.mp4
      ALK- First Line and Mechanism Of Resistance.mp4
      Antibody Drug Conjugates for HER2 Negative Breast Cancer- A Revolution in Chemotherapy for Breast Cancer.mp4
      Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer.mp4
      Artificial Intelligence and Modern Medical Practice- Do’s and Don’ts.mp4
      Bladder Cancer- Novel Insights and Recent Approvals.mp4
      Cancer Care Disparities in Puerto Rico.mp4
      Cancer Genetic Risk Factors- What’s New and What You Need to Know..mp4
      CAR-T Cell Therapy in Lymphomas- 7-Years Later.mp4
      Challenges in Lung Cancer Pathology- Biomarkers.mp4
      CLL- Therapeutic Advances in 2024.mp4
      Colorectal Cancer- Novel Treatment Paradigms.mp4
      Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against).mp4
      Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor).mp4
      Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance.mp4
      Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cance_2.mp4
      Cost and Access to Novel Therapeutic Agents. Where Are The Obstacles..mp4
      ctDNA in Lung Cancer- Current State and Future Perspectives.mp4
      De Novo Acute Myeloid Leukemia.mp4
      Diabetes Management in the Face of Healthcare Disparities.mp4
      EGFR Exon 20 Insertions- Novel Agents.mp4
      End of Life Management- Oncologists’ Perspectives.mp4
      Equity and Equality for Minorities in Cancer Care.mp4
      Immunotherapy for Breast Cancer- Efficacy and Toxicity Considerations.mp4
      K-RAS Therapies in NSCLC.mp4
      Kidney Cancer- Novel Development in Targeted and Immunotherapy.mp4
      Leveraging NCODA Resources to Manage Patients on Oral Oncolytics.mp4
      Lifestyle Modifications in Reducing Risk of Recurrence.mp4
      los-noscm-2024-flyer.pdf
      Lung Cancer With EGFR Exon 19 and L858R Mutations- The Optimal Front Line Therapy.mp4
      Malignant Hematology and Use of Bi-specifics in Puerto Rico.mp4
      Melanoma- Novel Advances in Immunotherapy.mp4
      Metastatic Castration Resistant Prostate Cancer- Sequencing the Treatment.mp4
      Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy.mp4
      Neuro-Oncology- Novel Advances in Therapy.mp4
      Neurology Drug Update.mp4
      New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer.mp4
      Non Driver NSCLC-The Immunotherapy Strategy.mp4
      Novel Advances for Thyroid Carcinoma and Thymoma.mp4
      Novel Advances in T-Cell NHL Therapies.mp4
      Obesity Management with Incretin Therapies- Considerations for Patients with and without Type 2 Diabetes.mp4
      Optimal Surgical Approach in Early Stages NSCLC.mp4
      Other Driver Mutations- ROS-1, BRAF, MET and RET.mp4
      Pancreas, Hepatic and Cholangiocarcinoma- Advances in 2024.mp4
      Pharmacology I- What HemOnc Clinicians Must Know in Immunotherapy.mp4
      Prostate Cancer- Early and Locally Advanced Disease.mp4
      Role of Pharmacist in Vaccination–Challenges and Opportunities.mp4
      Screening in Lung Cancer- Challenges and Obstacles.mp4
      Sequencing Therapy in Relapsed-Refractory Myeloma Patients.mp4
      Small Cell Lung Cancer- Targeting This Difficult Target.mp4
      Soft Tissue and Osteosarcomas- Novel Advances in 2024.mp4
      Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR-ABL, FLT3, IDH1-2).mp4
      Testicular Cancer- The Old, The New, The Future.mp4
      Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies– Focus on PARPi and Other Targeted Ther.mp4
      Upper GI Cancer- Esophageal and Gastric-New Developments.mp4
      What Is Next After Osimertinib Progression..mp4